Judge Won’t Toss Birth Defect Claims In Zofran MDL

Law360, New York (January 22, 2016, 8:20 PM EST) -- A Massachusetts federal judge on Friday nixed GlaxoSmithKline PLC’s bid to dismiss all claims in multidistrict litigation alleging that the drug company’s “off-label” promotion of its anti-nausea drug Zofran for morning sickness led to birth defects, saying that the bid seems to be premature at best.

U.S. District Judge F. Dennis Saylor IV denied the pharmaceutical company’s motion to dismiss, saying that he was loath to dismiss claims without giving the families the chance to develop facts. GSK had argued that the families state law claims were preempted by federal law under the U.S. Supreme Court decision in Wyeth v. Levine....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS